FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2741328596> ?p ?o ?g. }

• W2741328596 abstract "The use of the point-of-care lateral flow lipoarabinomannan (LF-LAM) test may expedite tuberculosis (TB) diagnosis in HIV-positive patients. However, the test's clinical utility is poorly defined outside sub-Saharan Africa.The study enrolled consecutive HIV-positive adults at a tertiary referral hospital in Yangon, Myanmar. On enrolment, patients had a LF-LAM test performed according to the manufacturer's instructions. Clinicians managing the patients were unaware of the LF-LAM result, which was correlated with the patient's clinical course over the ensuing 6 months.The study enrolled 54 inpatients and 463 outpatients between July 1 and December 31, 2015. On enrolment, the patients' median (interquartile range) CD4 T-cell count was 270 (128-443) cells/mm3. The baseline LF-LAM test was positive in 201/517 (39%). TB was confirmed microbiologically during follow-up in 54/517 (10%), with rifampicin resistance present in 8/54 (15%). In the study's resource-limited setting, extrapulmonary testing for TB was not possible, but after 6 months, 97/201 (48%) with a positive LF-LAM test on enrolment had neither died, required hospitalisation, received a TB diagnosis or received empirical anti-TB therapy, suggesting a high rate of false-positive results. Of the 97 false-positive tests, 89 (92%) were grade 1 positive, suggesting poor test specificity using this cut-off. Only 21/517 (4%) patients were inpatients with TB symptoms and a CD4 T-cell count of < 100 cells/mm3. Five (24%) of these 21 died, three of whom had a positive LF-LAM test on enrolment. However, all three received anti-TB therapy before death - two after diagnosis with Xpert MTB/RIF testing, while the other received empirical treatment. It is unlikely that knowledge of the baseline LF-LAM result would have averted any of the study's other 11 deaths; eight had a negative test, and of the three patients with a positive test, two received anti-TB therapy before death, while one died from laboratory-confirmed cryptococcal meningitis. The test was no better than a simple, clinical history excluding TB during follow-up (negative predictive value (95% confidence interval): 94% (91-97) vs. 94% (91-96)).The LF-LAM test had limited clinical utility in the management of HIV-positive patients in this Asian referral hospital setting." @default.
• W2741328596 created "2017-08-08" @default.
• W2741328596 creator A5000733629 @default.
• W2741328596 creator A5006710346 @default.
• W2741328596 creator A5010909343 @default.
• W2741328596 creator A5017121398 @default.
• W2741328596 creator A5021449612 @default.
• W2741328596 creator A5023618896 @default.
• W2741328596 creator A5030093684 @default.
• W2741328596 creator A5032095213 @default.
• W2741328596 creator A5054594428 @default.
• W2741328596 creator A5063673979 @default.
• W2741328596 date "2017-08-04" @default.
• W2741328596 modified "2023-10-10" @default.
• W2741328596 title "The clinical utility of the urine-based lateral flow lipoarabinomannan assay in HIV-infected adults in Myanmar: an observational study" @default.
• W2741328596 cites W1517960866 @default.
• W2741328596 cites W1970212454 @default.
• W2741328596 cites W1972048628 @default.
• W2741328596 cites W1981750380 @default.
• W2741328596 cites W1999408007 @default.
• W2741328596 cites W2020672863 @default.
• W2741328596 cites W2034321374 @default.
• W2741328596 cites W2051534485 @default.
• W2741328596 cites W2064642471 @default.
• W2741328596 cites W2073993234 @default.
• W2741328596 cites W2079716870 @default.
• W2741328596 cites W2081418446 @default.
• W2741328596 cites W2088125673 @default.
• W2741328596 cites W2089197323 @default.
• W2741328596 cites W2090102465 @default.
• W2741328596 cites W2092713390 @default.
• W2741328596 cites W2101359514 @default.
• W2741328596 cites W2103261662 @default.
• W2741328596 cites W2103345425 @default.
• W2741328596 cites W2107158674 @default.
• W2741328596 cites W2109028417 @default.
• W2741328596 cites W2109885966 @default.
• W2741328596 cites W2116938631 @default.
• W2741328596 cites W2117729186 @default.
• W2741328596 cites W2127073450 @default.
• W2741328596 cites W2200954247 @default.
• W2741328596 cites W2294971061 @default.
• W2741328596 cites W2296710870 @default.
• W2741328596 cites W2303072494 @default.
• W2741328596 cites W2312747026 @default.
• W2741328596 cites W2369312856 @default.
• W2741328596 cites W2385561666 @default.
• W2741328596 cites W2403671454 @default.
• W2741328596 cites W2428244928 @default.
• W2741328596 cites W2569826116 @default.
• W2741328596 cites W2591803653 @default.
• W2741328596 cites W2596419558 @default.
• W2741328596 cites W2620872726 @default.
• W2741328596 cites W2024882041 @default.
• W2741328596 doi "https://doi.org/10.1186/s12916-017-0888-3" @default.
• W2741328596 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5543584" @default.
• W2741328596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28774293" @default.
• W2741328596 hasPublicationYear "2017" @default.
• W2741328596 type Work @default.
• W2741328596 sameAs 2741328596 @default.
• W2741328596 citedByCount "22" @default.
• W2741328596 countsByYear W27413285962018 @default.
• W2741328596 countsByYear W27413285962019 @default.
• W2741328596 countsByYear W27413285962020 @default.
• W2741328596 countsByYear W27413285962021 @default.
• W2741328596 countsByYear W27413285962022 @default.
• W2741328596 countsByYear W27413285962023 @default.
• W2741328596 crossrefType "journal-article" @default.
• W2741328596 hasAuthorship W2741328596A5000733629 @default.
• W2741328596 hasAuthorship W2741328596A5006710346 @default.
• W2741328596 hasAuthorship W2741328596A5010909343 @default.
• W2741328596 hasAuthorship W2741328596A5017121398 @default.
• W2741328596 hasAuthorship W2741328596A5021449612 @default.
• W2741328596 hasAuthorship W2741328596A5023618896 @default.
• W2741328596 hasAuthorship W2741328596A5030093684 @default.
• W2741328596 hasAuthorship W2741328596A5032095213 @default.
• W2741328596 hasAuthorship W2741328596A5054594428 @default.
• W2741328596 hasAuthorship W2741328596A5063673979 @default.
• W2741328596 hasBestOaLocation W27413285961 @default.
• W2741328596 hasConcept C119060515 @default.
• W2741328596 hasConcept C126322002 @default.
• W2741328596 hasConcept C142724271 @default.
• W2741328596 hasConcept C187212893 @default.
• W2741328596 hasConcept C23131810 @default.
• W2741328596 hasConcept C2776056871 @default.
• W2741328596 hasConcept C2777975735 @default.
• W2741328596 hasConcept C2781069245 @default.
• W2741328596 hasConcept C71924100 @default.
• W2741328596 hasConceptScore W2741328596C119060515 @default.
• W2741328596 hasConceptScore W2741328596C126322002 @default.
• W2741328596 hasConceptScore W2741328596C142724271 @default.
• W2741328596 hasConceptScore W2741328596C187212893 @default.
• W2741328596 hasConceptScore W2741328596C23131810 @default.
• W2741328596 hasConceptScore W2741328596C2776056871 @default.
• W2741328596 hasConceptScore W2741328596C2777975735 @default.
• W2741328596 hasConceptScore W2741328596C2781069245 @default.
• W2741328596 hasConceptScore W2741328596C71924100 @default.
• W2741328596 hasFunder F4320334705 @default.
• W2741328596 hasIssue "1" @default.
• W2741328596 hasLocation W27413285961 @default.

• next